BTC Health Limited
BTC.AX
Australian Securities Exchange0.06
AUD
- -
- -
BTC Health Limited
BTC.AX
(Australian Securities Exchange)
Recent
price
0.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BTC Health Limited (ASX:BTC) is an Australia-based ASX-listed Pooled Development Fund that makes active investments in businesses which acquire, develop, and distribute specialized medical products and pharmaceuticals in Australia and New Zealand; the company, founded in 2000 and headquartered in Hawthorn, Victoria, operates through three wholly-owned subsidiaries--BTC Speciality Health, BTC Pharma, and BTC Cardio--targeting public and private hospitals with therapeutic areas including acute pain management, neuro-spinal surgery, cardiothoracic procedures, critical care, and niche pharmaceuticals for rare diseases. BTC Speciality Health commercializes medical devices and consumables such as elastomeric and electronic infusion pumps including Elasto-Q and Rhythmic Evolution for post-operative pain and regional anaesthesia, Rhythmic Infusion Pumps, Tiva Infusion and Nerve Catheter Kits, tissue and bone biopsy needles including Bonopty Coaxial Bone Biopsy and Rebellion Bone Removal System, bone cement injectors, pedicle access kits, and radiological markers from partners like IZI Medical and Ilumark; BTC Cardio supplies highly specialized cardiovascular equipment and single-use consumables used by cardiac surgeons and critical care perfusionists, encompassing cardiopulmonary bypass oxygenators, ECLS Extracorporeal Life Support systems, PEARS personalized external aortic root support grafts, heart valves including Perceval Plus sutureless aortic tissue valves, Carbomedics mechanical valves for aortic and mitral replacement, and Memo 4D mitral valve rings, alongside products from Wexler Surgical and TeDan; BTC Pharma handles registration, sales, and marketing of specialized pharmaceuticals such as PBS-listed Bronchitol for cystic fibrosis treatment and Aridol, serving niche markets and rare diseases. The company maintains a national footprint with seven ISO-certified warehouses, ISO 13485 quality management systems, TGA registration, and direct access to over 1,450 hospitals across Australia and New Zealand, delivering daily to metropolitan facilities and within 48 hours to regional ones while supporting reimbursement through the Prescribed List of Medical Devices, state health tenders, and private insurance. Recent developments include BTC Cardio's exclusive distribution partnership with Corcym effective January 2025, assuming operations of its Australia/New Zealand heart valve business to add $3.6 million in annual revenue from Perceval Plus, Carbomedics, and Memo 4D products with immediate profitability contribution; securing a $5 million five-year ECMO tender with Royal Children's Hospital Melbourne in 2024 and a $0.5 million order from Women's and Children's Hospital Adelaide in July 2025; indefinite extension of the Bronchitol and Aridol license with Arna Pharma effective February 2025 granting royalties and first right of refusal on its specialty pipeline; addition of infusion pumps like Elasto-Q and Rhythmic to the Prescribed List for reimbursement; FY25 consolidated revenue growth of 25% to $10.2 million with gross profit up 19% to $4.3 million and adjusted EBITDA of $0.2 million; and diversification via four new supplier agreements expanding to over 240 active product lines.